FDA Approves Telix's Pixclara, First FET-PET Imaging Drug for Glioma Brain Cancer

The U.S. Food and Drug Administration (FDA) has approved Telix's New Drug Application (NDA) for Pixclara (floretyrosine F 18 or 18F-FET), making it the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Pixclara is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients aged 1 month and older.